A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder

References

• Asberg M, Cronholm B, Sjoquvist F, Tuck D. Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J 1971; 3: 331–334
   PubMed Web of Science ®Google Scholar
• Benfield P, Ward A. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drug 1986; 13: 313–334
   Google Scholar
• Brosen K. Differences in interactions of SSRIs. Int Clin Psychopharmacol 1998; 13(Suppl 5)45–47
   Web of Science ®Google Scholar
• Brosen, K, Skjelbo, E, Rasmussen, BB, Poulsen, HE, Loft. 1993. Fluvoxamine is a potent inhibitor of cytochrome P450 1A2. Biochem Pharmacol, 45:1211–1214.
   PubMed Web of Science ®Google Scholar
• Carrillo JA, Dahl ML, Svensson JO, Alm C, Rodriguez I, Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2. Clin Pharmacol Ther 1996; 60: 183–190
   PubMed Web of Science ®Google Scholar
• De Wilde JEM, Doogan DP. Fluvoxamine and clomipramine in endogeneous depression. J Affect Disord 1982; 4: 249–259
   PubMed Web of Science ®Google Scholar
• Gerstenberg G, Aoshima T, Fukusawa T, Yoshida K, Takahashi H, Higuchi H, et al. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentarations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology 2003; 167: 443–448
   PubMed Web of Science ®Google Scholar
• Glassman AH, Perel JM, Shostak M, Kantor SJ, Fleiss JL. Clinical implication of imipramine plasma levels for depressive illness. Arch Gen Psychiatry 1977; 34: 197–204
   PubMed Web of Science ®Google Scholar
• Ikenouchi-Sugita A, Yoshimura R, Hori H, Ueda N, Nakamura J. Therapeutic drug monitoring of plasma fluvoxamine levels for treating bulimia nervosa. Psychiatry Clin Neurosci 2007; 61: 452
   PubMedGoogle Scholar
• Kasper S, Dotsch M, Kick H, Viera A, Möller HJ. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol 1993; 3: 13–21
   PubMedGoogle Scholar
• Mihara K, Yasui-Furukori N, Kondo T, Ishida M, Ono S, Ohkubo T, et al. Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients. Ther Drug Monit 2002; 24: 563–566
   PubMed Web of Science ®Google Scholar
• Nelson JC, Jatlow P, Quinlan DM, Bowers MB. Desipramine plasma concentration and antidepressant response. Arch Gen Psychiatry 1982; 39: 1419–1422
   PubMed Web of Science ®Google Scholar
• Otani K, Kaneko S, Sasa H, Kondo T, Fukushima Y. Is there a therapeutic window for plasma concentration of mianserin plus desmethylmianserin?. Hum Psychopharmacol 1991; 6: 243–248
   Web of Science ®Google Scholar
• Palmer KJ, Benfield P. Fluvoxamine: an overview of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. CNS Drugs 1994; 1: 57–87
   Web of Science ®Google Scholar
• Papakostas GI, Charles D, Fava M. Are typical starting doses of the selective serotonin reuptake inhibitors sub–optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry 2007; 13: 1–8
   Google Scholar
• Perucca KJ, Gatti G, Spina E. Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1994; 27: 175–190
   PubMed Web of Science ®Google Scholar
• Ruhe HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006; 67: 1836–1855
   PubMed Web of Science ®Google Scholar
• Sandson NB. Drug Interactions Case Book. American Psychiatric Publishing, Washington, DC 2003
   Google Scholar
• Ueda N, Yoshimura R, Shinkai K, Terao T, Nakamura J. Characteristics of fluvoxamine-induced nausea. Psychiatry Res 2001; 104: 259–264
   PubMedGoogle Scholar
• Ueda, N, Yoshimura, R, Nakamura, J. 2008. Fluvoxamine improves some depressive symptoms by influencing noradrenergic neurons. Psychiatry Res, in press
   Google Scholar
• Vandel P. Antidepressant drugs in the elderly-role of the cytochrome P450 2D6. World J Biol Psychaitry 2003; 4: 74–80
   PubMed Web of Science ®Google Scholar
• Von Moltke LL, Greenblatt DJ, Court MH. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995; 15: 125–131
   PubMed Web of Science ®Google Scholar